(CercleFinance.com) – Sanofi announces that the phase III study devoted to efanesoctocog alpha once a week in the treatment of hemophilia A has reached its primary endpoint and has allowed the prevention of bleeding episodes in a significant way. clinically significant.
For the primary secondary endpoint, it was superior to prior factor VIII prophylaxis in preventing bleeding, with a clinically and statistically significant decrease in annualized bleeding rate.
Efanesoctocog alpha was well tolerated and no factor VIII inhibitors were detected in study participants. This data will form the basis of submissions to regulators around the world starting this year.